---
reference_id: "PMID:38490517"
title: Novel mechanisms involved in leptin sensitization in obesity.
authors:
- Pena-Leon V
- Perez-Lois R
- Villalon M
- Prida E
- Muñoz-Moreno D
- Fernø J
- Quiñones M
- Al-Massadi O
- Seoane LM
journal: Biochem Pharmacol
year: '2024'
doi: 10.1016/j.bcp.2024.116129
content_type: abstract_only
---

# Novel mechanisms involved in leptin sensitization in obesity.
**Authors:** Pena-Leon V, Perez-Lois R, Villalon M, Prida E, Muñoz-Moreno D, Fernø J, Quiñones M, Al-Massadi O, Seoane LM
**Journal:** Biochem Pharmacol (2024)
**DOI:** [10.1016/j.bcp.2024.116129](https://doi.org/10.1016/j.bcp.2024.116129)

## Content

1. Biochem Pharmacol. 2024 May;223:116129. doi: 10.1016/j.bcp.2024.116129. Epub 
2024 Mar 13.

Novel mechanisms involved in leptin sensitization in obesity.

Pena-Leon V(1), Perez-Lois R(1), Villalon M(1), Prida E(2), Muñoz-Moreno D(2), 
Fernø J(3), Quiñones M(4), Al-Massadi O(5), Seoane LM(6).

Author information:
(1)Grupo Fisiopatología Endocrina, Departamento de Endocrinología, Instituto de 
Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario 
Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela, Travesía da 
Choupana s/n, 15706 Santiago de Compostela, Spain.
(2)Translational Endocrinology group, Endocrinology Section, Instituto de 
Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario 
Universitario de Santiago (IDIS/CHUS), Santiago de Compostela, Travesía da 
Choupana s/n, 15706 Santiago de Compostela, Spain.
(3)Hormone Laboratory, Department of Biochemistry and Pharmacology, Haukeland 
University Hospital, 5201 Bergen, Norway.
(4)Grupo Fisiopatología Endocrina, Departamento de Endocrinología, Instituto de 
Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario 
Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela, Travesía da 
Choupana s/n, 15706 Santiago de Compostela, Spain; CIBER de Fisiopatología de la 
Obesidad y la Nutrición, Instituto de Salud Carlos III, Madrid, Spain.
(5)Translational Endocrinology group, Endocrinology Section, Instituto de 
Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario 
Universitario de Santiago (IDIS/CHUS), Santiago de Compostela, Travesía da 
Choupana s/n, 15706 Santiago de Compostela, Spain; CIBER de Fisiopatología de la 
Obesidad y la Nutrición, Instituto de Salud Carlos III, Madrid, Spain. 
Electronic address: omar.al-massadi.iglesias@sergas.es.
(6)Grupo Fisiopatología Endocrina, Departamento de Endocrinología, Instituto de 
Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario 
Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela, Travesía da 
Choupana s/n, 15706 Santiago de Compostela, Spain; CIBER de Fisiopatología de la 
Obesidad y la Nutrición, Instituto de Salud Carlos III, Madrid, Spain. 
Electronic address: luisamaria.seoane@usc.es.

Leptin is a hormone that is secreted by adipocytes in proportion to adipose 
tissue size, and that informs the brain about the energy status of the body. 
Leptin acts through its receptor LepRb, expressed mainly in the hypothalamus, 
and induces a negative energy balance by potent inhibition of feeding and 
activation of energy expenditure. These actions have led to huge expectations 
for the development of therapeutic targets for metabolic complications based on 
leptin-derived compounds. However, the majority of patients with obesity 
presents elevated leptin production, suggesting that in this setting leptin is 
ineffective in the regulation of energy balance. This resistance to the action 
of leptin in obesity has led to the development of "leptin sensitizers," which 
have been tested in preclinical studies. Much research has focused on generating 
combined treatments that act on multiple levels of the gastrointestinal-brain 
axis. The gastrointestinal-brain axis secretes a variety of different 
anorexigenic signals, such as uroguanylin, glucagon-like peptide-1, amylin, or 
cholecystokinin, which can alleviate the resistance to leptin action. Moreover, 
alternative mechanism such as pharmacokinetics, proteostasis, the role of 
specific kinases, chaperones, ER stress and neonatal feeding modifications are 
also implicated in leptin resistance. This review will cover the current 
knowledge regarding the interaction of leptin with different endocrine factors 
from the gastrointestinal-brain axis and other novel mechanisms that improve 
leptin sensitivity in obesity.

Copyright © 2024 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.bcp.2024.116129
PMID: 38490517 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of competing interest The authors 
declare that they have no known competing financial interests or personal 
relationships that could have appeared to influence the work reported in this 
paper.